Schering-Plough Touts Claritin Successor

Schering-Plough almost has stopped promoting its top-selling drug Claritin, and has begun a mammoth marketing campaign for its successor, Clarinex. In 1999, the company was not able to obtain a Congress-approved extension on Claritin's patent. Schering-Plough is calling Clarinex "more potent," says drug-marketing research firm ImpactRx, but there is no evidence that Clarinex is more efficient than Claritin, reports say.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care